Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Oct;4(4):618-26.
doi: 10.1016/j.nurt.2007.07.008.

Corticosteroids for multiple sclerosis: I. Application for treating exacerbations

Affiliations
Review

Corticosteroids for multiple sclerosis: I. Application for treating exacerbations

Elliot M Frohman et al. Neurotherapeutics. 2007 Oct.

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disorder characterized by a multiphasic course of neurological exacerbations, periods of clinical remission, and, in most patients, ultimately progressive deterioration of functional capabilities. The relapsing-remitting phase of the disease involves acute interruption in neurological functioning relating to areas of inflammation in discrete central-tract systems. The treatment of MS exacerbations with anti-inflammatory agents such as corticosteroids and adrenocorticotropic hormone has represented an established practice throughout the neurology community. Although there is scientific rationale supporting application of these agents for this purpose, the broad diversity of approaches to using these drugs in clinical practice is a derivative of expert opinion and anecdotal experience. Ultimately, the treatment of MS-related exacerbations is part science, but mostly art. This review discusses the pharmacology of these agents, to better understand how they may act to mitigate attacks and to provide some practical formulations for how to use them in the clinic for the benefit of patients.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Uhthoff W. Untersuchungen über die bei der multiplen Herdsklerose vorkommenden Augenstorungen [In German] Arch Psychiatr Nervenkrankh. 1889;20:55–55.
    1. Hansen BS, Hussain RZ, Lovett-Racke AE, Thomas JA, Racke MK. Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity. J Neuroimmunol. 2006;172:94–103. doi: 10.1016/j.jneuroim.2005.11.006. - DOI - PubMed
    1. Goodin D, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169–178. - PubMed
    1. Dalakas MC. Current treatment of the inflammatory myopathies. Curr Opin Rheumatol. 1994;6:595–601. doi: 10.1097/00002281-199411000-00008. - DOI - PubMed
    1. Kirwan JR, The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med. 1995;333:142–146. doi: 10.1056/NEJM199507203330302. - DOI - PubMed

Publication types

MeSH terms

Substances